INTRODUCTION
Psychosis is the term given to the more severe forms of psychiatric disorder, during which hallucinations or delusions, violence and impaired insight may occur. 1 Psychotic disorders is reflected as significant psycho logical and social repercussions for everyday living. 2 Around three percent experience psychosis, more frequent than diabetes. Unlike infec tion, where the cause and effect are clear, most CNS ailments follow a complex biology, and have differing outcomes depending on predisposing factors. Even though the available drugs fulfil the requirements in the segment, there is need for more effective drugs that are better tolerated and cost effective to enhance the long term compliance. 3 Psychosis is explained in terms of neurotransmitter dopamine. It is assumed that the dopamine of psychosis has been influential and states that psychosis results from an over activity of dopamine function in the brain, in particular the mesolimbic pathway. There exists a complex relationship in between dopamine and psychosis. The dopamine receptor D2 suppresses and D1 receptor increases adenylate cyclase activity. The blocked dopamine spills over to the D1 receptors during the adminis tration of D2 blocking drugs. The increased adenylate cyclase activity affects genetic expression in the nerve cell; usually this process takes certain time period. Hence, antipsychotic drugs take a week or two to reduce the symptoms of psychosis. 4 Antipsychotics are divided into two categories. The first category is called as typical antipsychotics and also referred to as first generation antipsychotics or classical neuroleptics or major tranquilizers or conven tional antipsychotics. Second category drugs, known as atypical antipsy chotics or second generation antipsychotics, are used to treat psychiatric conditions.
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MATERIALS AND METHODS
Materials
Instrumentation
The melting points of compounds were measured in open capillaries in electrical heated melting point apparatus of Jindal, S.M. Scientific Instru ments Pvt. Ltd., New Delhi. IR spectra were recorded on Perkin Elmer FTIR Spectrometer Spectrum Two and values are expressed in wave numbers (cm 1 ).
1 HNMR spectrums were recorded on JEOL, JNMECS 400 MHz using ChloroformD (CDCl 3 ) as solvent. Tetramethylsilane (TMS, δ0.00 ppm) was used as internal standard in 1 HNMR. Purity and Mass analysis were recorded on WATERSQTOF PremierHAB213 mass spectrometer. All the chemicals were procured from Aldrich, Qualikems and Merck Chemicals.
Animals
White Albino Rats of Wister strain weighing 150 ± 5 g and Swiss albino mice of both gender weighing 20 ± 5 g and studies on them. After observing the usual formalities lay down byIAEC as per provisions made by CPCSEA. All the animals were housed in laboratory cages in animal house maintained at 23 ± 2 ºC under standard light/dark cycle. All the animals had free access to standard food pellets and filtered water.
Drugs
Diazepam (Calmtack, Indus Pharma Pvt. Ltd.) was dissolved in DMSO (2 mg/kg body weight), Apomorphine (Zyprima, Cadila Pharmaceuticals Ltd) (2.5 mg/kg body weight, ip), Haloperidol (Haldol, East West Pharma) (2.5 mg/kg body weight, ip) were dissolved in normal saline. Control animals were treated with distilled water in the same period.
Plant material
Stem bark of Crataeva nurvala was authenticated from Chandra Shekhar Azad University of Agriculture & Technology, Kanpur (CSA/DOH/ 201516/ 31). The plants were selected on the basis of their folk medicinal value. Lupeol was isolated from the hexane fraction of the stem bark of Crataeva nurvula and it was named as compound1. It displayed a mo lecular ion peak at m/z 426 for molecular ion [M] + of lupeol and a mo lecular formula C 30 H 50 O. The 1H and 13C NMR spectra were found ex hibiting characteristic signals for lup20 (29)en3ol. 6 The structure was confirmed by comparison of spectroscopic data of the compound1 to those described for lupeol and confirmation of the lupeol was also done by thin layer chromatography (TLC).
METHODS
EXTRACTION OF LUPEOL (L-1)
Coarsely powdered (2 kg) raw material of C.nurvala stem bark was extracted by cold maceration with 95% ethanol and concentrated through rotary vacuum evaporator at 40 0 C under reduced pressure. The concentrated ethanolic extract (130 g) was defatted with petroleum ether and fractionated with chloroform successively. The chloroform fraction was concentrated under reduced pressure to afford chloroform soluble light brownish residue (30 g). The compounds were isolated from chlo roform fraction through column chromatography using gradient elution technique. The progress of separation was monitored by TLC (silica gel G 60 F254 plates, Merck). Fractions eluted with nhexane and EtOAc (8:2) resulted an amorphous yellowish white residue which after crystal lization with methanol provides colorless crystalline substance termed as Lupeol (L1) (16 g) (Figure 1 
CHEMICAL MODIFICATIONS OF LUPEOL (L-1)
Step-1: Chemical modification at C-30
Lupeol (1 gm, 2.35 mm) was refluxed with selenium dioxide in dioxane with 34 drops of distilled water for 1012 hours. After consumption of all of lupeol, reaction mixture was treated with 2.5% aq. KOH, and Organic layer was washed with distilled water till it became neutral, then dried over sodium sulphate, and was evaporated under vacuum. This reaction mixture was chromatographed over silica gel column and was eluted with n hexane/ ethyl acetate with (9:1) (8:2) (7:3). Finally required pure lupeol aldehyde (LA1) was obtained. Formation of LA1 generated an additional functional group (Alde hyde) in lupeol which can be used to build different heterocycles on this bifunctional three carbon unit. In NMR spectrum, a new proton at 9.5 appeared along with olefinic proton.
Step-2: Chemical modification at C-30 aldehyde Second step was accomplished by doing changes in the isopropenyl side chain of LA1. Reaction with histamine: LA1 (1 mole) was refluxed with Histamine (1 mole) in methanol for 12 h. After that reaction product was separated by ethyl acetate and water. Then sodium sulphate was added in organic layer and filtered in order to get LAH2. LAH-2: M.P.: 217218 ºC. FTIR spectra showed 3400 cm 1 Reaction with 2-Aminopyridine: LA1 (1 mole) was refluxed with 2 Aminopyridne (1 mole) in methanol for 12 h. After that the reaction product was separated by ethyl acetate and water. Then sodium sulphate was added in organic layer and filtered in order to get LAP2. Reaction with Thiosemicarbazide: LA1 (1 mole) was refluxed with Thiosemicarbazide (1 mole) in methanol for 12 h. After that the reaction product was separated by ethyl acetate and water. The organic layer was taken and added sodium sulfate and then filtered it to obtain LATS2. Step-3: Further modification of synthesized modified products LAH2 (1 mole) was refluxed with Sodium Borohydride (1.5 mole) in methanol for 12 h. Then the reaction product was separated by ethyl ac etate and water. The organic layer was taken and sodium sulphate was added and filtered to obtain LAH3. LAP2 (1 mole) was refluxed with Sodium Borohydride (1.5 mole) in methanol for 12 h. After that the reaction product was separated by ethyl acetate and water. The organic layer was taken and added sodium sulfate and then filtered it to obtain LAP3. (s,1H,NH 2 ), δ5.42 (s,1H,CN), δ5.18 (s,2H,CH 2 ), δ2.2 (m,1H,NH 
LATS-
2: M.P.: 220ºC. FTIR spectra showed 3431 cm 1 (OH), 2990
ACUTE TOXICITY STUDY
The acute toxicity study of potent compounds was performed as per the OECD guideline. The albino mice of either sex (body weight 2025 g) were used. Thepotent compound was administered by oral route at different dose levels ingroup of 3 animals each. Animals were observed individually after administration at leastonce during the first 30 minutes, periodically during the first 24 hur and then they were sacrificed.
ANTI-PSYCHOTIC ACTIVITY (ACTOPHOTOMETER)
Experimental study protocol has been approved by the Institutional Animal Ethics Committee (IAEC) constituted as per the guidelines laid by the committee for the purpose of control and supervision of experiments on Animals (CPCSEA) (1273/AC/09). Actophotometer was performed by administering Diazepam (2mg/kg body weight) and syn thesized molecules (LAH3, LAP3, LAPEA3, LAMP3, LATS3, LAS3) (n=3) into different groups of White Albino Rats of Wister strain (150170 g). Rats were maintained on laboratory stock diet. They were fasted for 24 h before starting the experiment. The rats were numbered and weighed. The Actophotometer was switched on and the rats were placed individually in the activity case for 10 min. The basal locomotor activity score of all rats were noted. Standard, Test, Control were injected on each rats of proposed groups and after 30 min. each animals were retested for 10 min. They were divided into three groups each comprised of three rats. The groups are: Control group three rats received 0.8 ml of DMSO, Standard group three rats received oral dose of Diazepam 2 mg/kg body weight, Test group divided into first to six groups, each containing three rats, received 250 mg of test drug per kg body weight LAMA2 (1 mole) was refluxed with Sodium Borohydride (1.5 mole) in methanol for 12 h. After that the reaction product was separated by ethyl acetate and water. The organic layer was taken and added sodium sulfate and then filtered it to give the product LAMA3. LAMA-3: M.P.: 230ºC. FTIR spectra showed 3310 cm 1 (OH), 2914 cm 1 (=CH), 2844 cm LATS2 (1 mole) was refluxed with Sodium Borohydride (1.5 mole) in methanol for 12 h. After that the reaction product was separated by ethyl acetate and water. The organic layer was taken and added sodium sulfate and then filtered it to give the product LATS3. LATS-3: M.P.: 231ºC. FTIR spectra showed 3367 cm 1 Ankita et al.: Antipsychotic activity of lupeol and its derivatives activity when compared with control ( Figure 2 ); however; this psychosis was less with drug derivatives treated group than diazepamtreated group.
COMPULSIVE BEHAVIOUR (STEREOTYPY) IN PLUS MAZE MODEL
All the drug derivative compounds were subjected to pharmacological evaluation to determine their behaviour symptoms, inhibition of apomor phine induced Rearing, Sniffing, Licking. Swiss albino mice (three mice in each group) of either sex (2025 g) were used andhoused per cage in standard laboratory conditions (12 h light/ dark cycle, 22 ± 2 ºC room temperature). Food and water were available ad libitum. All experiments were approved byinstitutional ethical Committee. All synthesized compounds were suspended in 1% solution of apomorphine in distilled water and administered by the intraperitoneal (i.p) route. The changes in the behavior symptoms were noted down for aninterval of 30 min for 3 h and then after 24 h, the cages were inspected for anymortality of the animals. Haloperidol (2 mg/kg i.p.) and drug derivatives (250 mg/kg, oral) significantly (P < 0.001) exhibited psychosis; as evident from decreased rearing, sniffing, and licking behaviour as compared with control ( Figure 3 ). dissolved in 1ml of DMSO. The synthesized compounds LAH3, LAP3, LAPEA3, LAMP3, LATS3 and LAS3 were selected and evaluated for their AntiPsychotic Activity using Actophotometer.
Statistical analysis
Data were analyzed by analysis of variance test followed by turkey's test.
All the results were expressed as mean ± SEM. P < 0.05 was considered significant. Percent reduction in activity score and fall off time were calculated with reference to respective basal recordings. 
COMPULSIVE BEHAVIOUR (STEREOTYPY) IN PLUS MAZE MODEL
Statistical analysis
Data were analyzed by analysis of variance test followed by turkey's test. All the results were expressed as mean ± SEM. P < 0.05 was considered significant. Percent reduction in activity score and fall off time were calculated with reference to respective basal recordings.
RESULT AND DISCUSSION
Acute Toxicity Study
After Sacrifice infection was observed in intestine, stomach, liver and ulcer occurs in intestinal parts of animals at the various concentrations of drugs. The results of acute toxicity study showed no clinical signs of toxicity and mortality in the lupeol drug treated animals even after administration of 500 mg/kg dose (Table 1) . Hence, as per OECD guide lines lethal dose was assigned to be more than 1000 mg/kg. Onefourth of this lethal dose (250 mg/kg) was taken as effective dose for the study.
ANTI-PSYCHOTIC ACTIVITY (ACTOPHOTOMETER)
Effect of lupeol derivatives on animal behaviour was observed and it was found that there is significant difference between LAH3 and LAPEA3 occurs (P< 0.05) ( Table 2) . Diazepam (2.5 mg/kg, oral) and drug derivatives (250 mg/kg, oral) treated groups showed significant locometer 
PICTORIAL ABSTRACT ABOUT AUTHORS SUMMARY AND CONCLUSION
A series of compounds were prepared using the pathway shown in synthetic schemes (3.5). The target compounds were prepared by three steps procedure. In series A, in the first step Lupeol (L1) was reacted with selenium dioxide and few drops of water to give the product Lupeol aldehyde (LA1). In the second step, LA1 was reacted with the different amines to give the final products. At in the last step, the reduction dou ble bond at C30. All the target compounds were subjected to pharma cological evaluation for behaviorsymptoms, likes standing (rearing), continuous sniffing (touching the nose), and licking the body inhibition of apomorphine induced in elevated plus maze model .The semisyn thetic derivatives were also subjected to locomotor activity and result shown that compound LAH3 and LAPEA3 was found to be active. The acute toxicity of the potent compound in a series was also performed.
The pharmacological results suggested that the presence of heterocyclic amines in the ring increased the antipsychotic activity. This clearly demonstrate that 5 membered Histamine and aromatic amine such as phenyl ethyl amine increases the activity while other substituent has no effect on activity as compared to lupeol.Although inclusion of pyridine, piperazine, semicarbazide and thiosemicarbazide does not increase any effect. Only imidazoline and aromatic amine like phenyl ethyl amine shows the positive response. It is thus concluded that lupeol skeleton deserve further investigation for the development of more potent and nontoxic new agents for therapeutic use.
